10:18 AM EST - Aeterna Zentaris Inc : Has licensed the exclusive worldwide rights to develop, manufacture and commercialize targeted, highly specific, autoimmunity modifying proteins for the potential treatment of neuromyelitis optica spectrum disorder from the Julius-Maximilians-University Wuerzburg. Aeterna Zentaris Inc
shares T.AEZS are trading up $0.02 at $0.98.
